Imfinzi Padcev Bladder Cancer Approval: AstraZeneca Takes On Keytruda in Cisplatin-Free Surgery Setting
The FDA approved perioperative Imfinzi plus Padcev for muscle-invasive bladder cancer patients who cannot take cisplatin. VOLGA cut the risk of death by 42%, and the approval pits AstraZeneca against Merck while Padcev wins either way.